In addition, CALD1, TGFB3 and ANXA6 were identified as immune hub genes (MM > 0.85), which may serve as biomarkers for predicting the outcomes of patients with BLCA and selecting eligible patients for mRNA vaccination. The gene discussed is ANXA6; the disease is bladder transitional cell carcinoma.